Exagen (NASDAQ:XGN – Get Rating) had its price target lowered by analysts at Canaccord Genuity Group from $8.00 to $7.00 in a research note issued on Tuesday, The Fly reports. The firm presently has a "buy" rating on the stock. Canaccord Genuity Group's price objective suggests a potential upside of 105.88% from the stock's previous close.
A number of other equities research analysts have also recently issued reports on XGN. KeyCorp cut shares of Exagen from an "overweight" rating to a "sector weight" rating in a research note on Friday, August 5th. Canaccord Genuity Group dropped their price target on shares of Exagen from $8.00 to $7.00 and set a "buy" rating on the stock in a research note on Tuesday. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, Exagen has an average rating of "Moderate Buy" and a consensus price target of $11.75.
Get
Exagen alerts:
Exagen Price Performance
Shares of NASDAQ XGN opened at $3.40 on Tuesday. The stock has a market capitalization of $55.28 million, a price-to-earnings ratio of -1.50 and a beta of 1.17. Exagen has a 12 month low of $2.10 and a 12 month high of $12.89. The firm's 50 day simple moving average is $2.98 and its 200-day simple moving average is $4.83. The company has a debt-to-equity ratio of 0.43, a current ratio of 9.30 and a quick ratio of 9.30.
Institutional Trading of Exagen
Institutional investors and hedge funds have recently bought and sold shares of the stock. Russell Investments Group Ltd. purchased a new stake in Exagen in the 1st quarter valued at about $27,000. Intrust Bank NA purchased a new stake in Exagen during the second quarter worth about $57,000. First Bank & Trust increased its stake in Exagen by 47.1% during the second quarter. First Bank & Trust now owns 23,176 shares of the company's stock worth $133,000 after purchasing an additional 7,423 shares during the period. Advisors Capital Management LLC increased its stake in Exagen by 66.2% during the third quarter. Advisors Capital Management LLC now owns 67,923 shares of the company's stock worth $143,000 after purchasing an additional 27,050 shares during the period. Finally, Envestnet Asset Management Inc. increased its stake in Exagen by 7.7% during the first quarter. Envestnet Asset Management Inc. now owns 25,731 shares of the company's stock worth $207,000 after purchasing an additional 1,839 shares during the period. 65.94% of the stock is currently owned by hedge funds and other institutional investors.
About Exagen
(Get Rating)
Exagen Inc develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. It enables rheumatologists to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).
Read More
- Get a free copy of the StockNews.com research report on Exagen (XGN)
- Use The Airbnb Stock Implosion to Your Advantage
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- International Game Technology is Well Worth the Gamble
- Why Lowe's Is Up And Home Depot Down
- The TJX Companies Could Break Out To New Highs
Receive News & Ratings for Exagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exagen and related companies with MarketBeat.com's FREE daily email newsletter.
据The Fly报道,在周二发布的一份研究报告中,Canaccel Genuity Group的分析师将埃克森美孚(纳斯达克:XGN-GET评级)的目标价从8.00美元下调至7.00美元。该公司目前对该股的评级为“买入”。Canaccel Genuity Group的目标价显示,该股较前一交易日收盘价有105.88%的潜在上涨空间。
其他一些股票研究分析师最近也发布了关于XGN的报告。KeyCorp在8月5日星期五的一份研究报告中将Exagen的股票评级从“增持”下调至“行业权重”。周二,Canaccel Genuity Group将Exagen的目标价从8.00美元下调至7.00美元,并在一份研究报告中对该股设定了“买入”评级。一位股票研究分析师对该股的评级为持有,四位分析师对该股的评级为买入。根据MarketBeat的资料,Exagen的平均评级为“中等买入”,共识目标价为11.75美元.
到达
埃克森警报:
Exagen性价比
周二,纳斯达克XGN的股价开盘报3.4美元。该股市值为5,528万美元,市盈率为-1.5倍,贝塔系数为1.17。Exagen的12个月低点为2.10美元,12个月高位为12.89美元。该公司的50日简单移动均线切入位为2.98美元,200日简单移动均线切入位为4.83美元。该公司的债务权益比为0.43,流动比率为9.30,速动比率为9.30。
Exagen的制度性交易
机构投资者和对冲基金最近买卖了该股的股票。罗素投资集团有限公司(Russell Investments Group Ltd.)在第一季度购买了Exagen的新股份,价值约2.7万美元。InTrust Bank NA在第二季度购买了Exagen的新股份,价值约5.7万美元。First Bank&Trust在第二季度增持了47.1%的Exagen股份。First Bank&Trust在此期间又购买了7,423股,现在拥有23,176股该公司股票,价值13.3万美元。Advisors Capital Management LLC在第三季度增持了Exagen 66.2%的股份。Advisors Capital Management LLC在此期间额外购买了27,050股,现在拥有67,923股该公司股票,价值143,000美元。最后,Envestnet Asset Management Inc.在第一季度将其在Exagen的持股增加了7.7%。Envestnet Asset Management Inc.在此期间又购买了1,839股,现在拥有25,731股该公司股票,价值20.7万美元。65.94%的股票目前由对冲基金和其他机构投资者持有。
关于艾克森
(获取评级)
Exagen Inc.在美国开发和销售基于其细胞结合补体激活产品技术的各种测试产品,品牌为AVISE。它使风湿科医生能够通过自身免疫和自身免疫相关疾病的诊断、预后和监测来护理患者,包括系统性红斑狼疮(SLE)和类风湿性关节炎(RA)。
阅读更多内容
- 免费获取StockNews.com关于Exagen的研究报告(XGN)
- 利用爱彼迎股票的内爆对你有利
- 提供高股息收益的3只天然气股票
- 国际游戏技术值得赌一把
- 为什么Lowe‘s上升,Home Depot下降
- TJX公司可能突破新高
接受《Exagen Daily》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Exagen和相关公司的最新新闻和分析师评级的每日简明摘要。